Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
That research is important, but it is not proof that GLP-1s should be used casually or as microdoses for dementia prevention
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint 1,2,3 "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes," said In both trials, the overall safety and tolerability profile of orforglipron, as well as treatment discontinuation rates, were consistent with previous studies
Instead, providers typically consider a combination of factors before recommending any further increase, including how well a patient tolerated the previous stage, whether appetite and metabolic markers are trending in the expected direction, and whether any side effects reported at the current stage have resolved
It blocks that counter-signal, allowing bupropions appetite-reducing effect to stay switched on longer than it would on its own
Host: E
US$ 24.00
US$ 28.85
US$ 21.48
